Dr. Suzanne Merrill

When you're shining that blue light, just because of the inflammation where this optical imaging agent is going to accumulate to is not going to be only in cancer cells.

When you're shining that blue light, just because of the inflammation where this optical imaging agent is going to accumulate to is not going to be only in cancer cells.

When you're shining that blue light, just because of the inflammation where this optical imaging agent is going to accumulate to is not going to be only in cancer cells.

So there, in 2018, Danishman published in Neurologic Oncology some real-world data, which is really helpful to understand, again, you know, outside of the very strict criteria of a randomized trial, you know, how are people using this data and what are the results? And so through a U.S. kind of prospective multi-senator registry, they found that use of blue light

So there, in 2018, Danishman published in Neurologic Oncology some real-world data, which is really helpful to understand, again, you know, outside of the very strict criteria of a randomized trial, you know, how are people using this data and what are the results? And so through a U.S. kind of prospective multi-senator registry, they found that use of blue light

So there, in 2018, Danishman published in Neurologic Oncology some real-world data, which is really helpful to understand, again, you know, outside of the very strict criteria of a randomized trial, you know, how are people using this data and what are the results? And so through a U.S. kind of prospective multi-senator registry, they found that use of blue light

can result in a rate of upstaging of about 14%. And how that breaks down is that ultimately 8% of patients were identified with cancerous lesions, whereas with the white light, they were not. Okay, so that stages them to having cancer. And that 6% of patients actually had an increase in that risk status. What we were talking about before, you know, that vulnerable intermediate risk category was,

can result in a rate of upstaging of about 14%. And how that breaks down is that ultimately 8% of patients were identified with cancerous lesions, whereas with the white light, they were not. Okay, so that stages them to having cancer. And that 6% of patients actually had an increase in that risk status. What we were talking about before, you know, that vulnerable intermediate risk category was,

can result in a rate of upstaging of about 14%. And how that breaks down is that ultimately 8% of patients were identified with cancerous lesions, whereas with the white light, they were not. Okay, so that stages them to having cancer. And that 6% of patients actually had an increase in that risk status. What we were talking about before, you know, that vulnerable intermediate risk category was,

Where again, if they were found to have either a high-grade lesion, whereas initial white light resection would have only shown maybe a white low-grade lesion, or they would have found maybe a CIS lesion, then they're popping up into that high-risk category. And therefore, again, would be set on a path of recommended intervesicle therapy after their resection. So really important stuff for sure.

Where again, if they were found to have either a high-grade lesion, whereas initial white light resection would have only shown maybe a white low-grade lesion, or they would have found maybe a CIS lesion, then they're popping up into that high-risk category. And therefore, again, would be set on a path of recommended intervesicle therapy after their resection. So really important stuff for sure.

Where again, if they were found to have either a high-grade lesion, whereas initial white light resection would have only shown maybe a white low-grade lesion, or they would have found maybe a CIS lesion, then they're popping up into that high-risk category. And therefore, again, would be set on a path of recommended intervesicle therapy after their resection. So really important stuff for sure.

Yeah, no, that's a good question for sure. I think the data is more about showing kind of, again, risk migration in the non-muscle invasive categories rather than switching to a kind of T1 to T2 stage, for example. I think it certainly...

Yeah, no, that's a good question for sure. I think the data is more about showing kind of, again, risk migration in the non-muscle invasive categories rather than switching to a kind of T1 to T2 stage, for example. I think it certainly...

Yeah, no, that's a good question for sure. I think the data is more about showing kind of, again, risk migration in the non-muscle invasive categories rather than switching to a kind of T1 to T2 stage, for example. I think it certainly...

This technology really has shown us that it is this CIS, which, as we mentioned before, is a very elusive disease under normal, traditional white light capacity. And that ultimately, historically, we've done a very poor job in detecting CIS.

This technology really has shown us that it is this CIS, which, as we mentioned before, is a very elusive disease under normal, traditional white light capacity. And that ultimately, historically, we've done a very poor job in detecting CIS.

This technology really has shown us that it is this CIS, which, as we mentioned before, is a very elusive disease under normal, traditional white light capacity. And that ultimately, historically, we've done a very poor job in detecting CIS.

In 2023, there was a report looking at kind of a cystectomy database and looking at kind of what the path was retrieved from the, you know, whole mound specimen, the cystectomy, compared to what was their, you know, initial, you know, diagnosis from the TRBT preceding the cystectomy. And ultimately, 45% of cases actually missed CIS. So there is CIS in the cystectomy pathology and

In 2023, there was a report looking at kind of a cystectomy database and looking at kind of what the path was retrieved from the, you know, whole mound specimen, the cystectomy, compared to what was their, you know, initial, you know, diagnosis from the TRBT preceding the cystectomy. And ultimately, 45% of cases actually missed CIS. So there is CIS in the cystectomy pathology and